<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="mja252621" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med J Aust</journal-id><journal-id journal-id-type="iso-abbrev">Med J Aust</journal-id><journal-id journal-id-type="doi">10.5694/(ISSN)1326-5377</journal-id><journal-id journal-id-type="publisher-id">MJA2</journal-id><journal-title-group><journal-title>The Medical Journal of Australia</journal-title></journal-title-group><issn pub-type="ppub">0025-729X</issn><issn pub-type="epub">1326-5377</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40038047</article-id><article-id pub-id-type="pmc">PMC11972594</article-id>
<article-id pub-id-type="doi">10.5694/mja2.52621</article-id><article-id pub-id-type="publisher-id">MJA252621</article-id><article-id pub-id-type="other">mja24.00783.R1</article-id><article-categories><subj-group subj-group-type="JEL-classification"><subject>Environment and Public Health</subject></subj-group><subj-group subj-group-type="JEL-classification"><subject>Health Services Administration</subject></subj-group><subj-group subj-group-type="JEL-classification"><subject>Health Occupations</subject></subj-group><subj-group subj-group-type="overline"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Research and Reviews</subject><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Accountability, ambition, and quantifiable action in the carbon emission reduction plans of the ten largest pharmaceutical companies in Australia: a cross&#x02010;sectional analysis</article-title><alt-title alt-title-type="right-running-head">Accountability, ambition, and quantifiable action in the carbon emission reduction plans of the ten largest pharmaceutical companies in Australia: a cross&#x02010;sectional analysis</alt-title></title-group><contrib-group><contrib id="mja252621-cr-0001" contrib-type="author" corresp="yes"><name><surname>Burch</surname><given-names>Hayden</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8191-6066</contrib-id><xref rid="mja252621-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mja252621-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>burchh@unimelb.edu.au</email></address></contrib><contrib id="mja252621-cr-0002" contrib-type="author"><name><surname>Brown</surname><given-names>Georgia</given-names></name><xref rid="mja252621-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mja252621-cr-0003" contrib-type="author"><name><surname>Adler</surname><given-names>Oliver</given-names></name><xref rid="mja252621-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mja252621-cr-0004" contrib-type="author"><name><surname>Wong</surname><given-names>Jason</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6360-2525</contrib-id><xref rid="mja252621-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="mja252621-cr-0005" contrib-type="author"><name><surname>Winkel</surname><given-names>Kenneth D</given-names></name><xref rid="mja252621-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="mja252621-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Melbourne Medical School</named-content>
<institution>the University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">VIC</named-content>
</aff><aff id="mja252621-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Austin Health</institution>
<city>Melbourne</city>
<named-content content-type="country-part">VIC</named-content>
</aff><aff id="mja252621-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>New England Local Health District</institution>
<city>Newcastle</city>
<named-content content-type="country-part">NSW</named-content>
</aff><aff id="mja252621-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Melbourne School of Population and Global Health</named-content>
<institution>the University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">VIC</named-content>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<email>burchh@unimelb.edu.au</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>222</volume><issue seq="70">6</issue><issue-id pub-id-type="doi">10.5694/mja2.v222.6</issue-id><fpage>305</fpage><lpage>312</lpage><history>
<date date-type="received"><day>06</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>01</day><month>10</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 AMPCo Pty Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Medical Journal of Australia</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of AMPCo Pty Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:MJA2-222-305.pdf"/><abstract><title>Abstract</title><sec id="mja252621-sec-0001"><title>Objectives</title><p>To assess the commitment of the ten largest pharmaceutical companies operating in Australia to achieving net zero emissions by evaluating their accountability metrics, ambitions, and quantifiable actions taken.</p></sec><sec id="mja252621-sec-0002"><title>Study design</title><p>Cross&#x02010;sectional study; analysis of publicly available company reports published during 12 December 2015 &#x02013; 31 December 2023.</p></sec><sec id="mja252621-sec-0003"><title>Setting, participants</title><p>Ten largest pharmaceutical companies operating in Australia, defined by total pharmaceutical costs (to patients and Pharmaceutical Benefits Scheme) for PBS&#x02010;subsidised medications, as reported in PBS expenditure and prescriptions reports for 2020&#x02013;21 and 2022&#x02013;23.</p></sec><sec id="mja252621-sec-0004"><title>Main outcome measures</title><p>Content analysis of publicly available documents for the ten companies using modified criteria from the PricewaterhouseCoopers <italic toggle="no">Building blocks for net zero transformation framework</italic>, with three domains: accountability, ambition, and action; the Carbon Disclosure Project (CDP) grading; the Science Based Targets initiative (SBTi) approval system. We focused on measurement, target setting, and achievement of emission reductions, and ranked the environmental sustainability of companies using a points and colour coding system.</p></sec><sec id="mja252621-sec-0005"><title>Results</title><p>Three groups could be defined by evidence of their commitment to emissions reductions. The first &#x02014; companies leading emissions reduction efforts, with SBTi&#x02010;approved near term targets, consistent emissions monitoring, well defined commitments, and quantified evidence of action &#x02014; includes AstraZeneca, Novartis, Johnson &#x00026; Johnson, Bayer, and Merck &#x00026; Co. The second group &#x02014; companies that had made commitments to SBTi&#x02010;approved targets but their disclosure records are limited &#x02014; includes AbbVie and Roche. The third group &#x02014; without public commitments to achieving net zero emissions, minimal or no SBTi&#x02010;approved targets, and minimal disclosure or monitoring of emissions &#x02014; includes Viatris, Vertex, and Arrotex.</p></sec><sec id="mja252621-sec-0006"><title>Conclusions</title><p>The ten largest pharmaceutical companies in Australia are moving towards net zero greenhouse gas emissions at different rates. Gaps in standardised reporting processes should be closed, and further qualitative research on industry&#x02010;wide environmental sustainability policy and practice is needed.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mja252621-kwd-0001">Climate change</kwd><kwd id="mja252621-kwd-0002">Health policy</kwd><kwd id="mja252621-kwd-0003">Health systems</kwd><kwd id="mja252621-kwd-0004">Pharmacy</kwd></kwd-group><counts><fig-count count="1"/><table-count count="6"/><page-count count="8"/><word-count count="5900"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:06.04.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="mja252621-ntgp-3001"><fn id="mja252621-note-3001"><p>See Editorial (Bone)</p></fn></fn-group></notes></front><body id="mja252621-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="mja252621-blkfxd-0001"><p>
<bold>The known</bold>: The ramifications of climate change for health have led to calls for reductions of greenhouse gas emissions in all sectors. In Australia, the pharmaceutical industry is responsible for about 19% of greenhouse gas emissions in the health care sector.</p><p>
<bold>The new</bold>: Our assessment of their commitment, monitoring, and actions during 2015&#x02013;2023, based on publicly available documents, indicates that the ten largest pharmaceutical companies in Australia are moving to net zero emissions at different speeds.</p><p>
<bold>The implications</bold>: Our findings can assist policy makers and clinicians make informed decisions about low carbon suppliers of medicines and support emissions reduction efforts by pharmaceutical corporations.</p></boxed-text>
</p><p>Pharmaceutical companies have an environmental impact in terms of waste generation and disposal, greenhouse gas emissions, air pollution, and water, plastic, and energy consumption. In Australia, the pharmaceutical industry is responsible for about 19% of greenhouse gas emissions in the health care sector,<xref rid="mja252621-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> and receives about 16% of government spending on health, principally through Pharmaceutical Benefits Scheme (PBS) subsidies (2022&#x02013;23: $16.7 billion).<xref rid="mja252621-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>The 2015 United Nations Paris Agreement required countries to begin reporting and reducing carbon emissions.<xref rid="mja252621-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Several international protocols standardise monitoring and reporting, set science&#x02010;based emissions reduction targets, and promote accountability and measurable outcomes.<xref rid="mja252621-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="mja252621-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="mja252621-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Standards improve sustainability disclosure and complement rather than substitute for each other.<xref rid="mja252621-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Under the Greenhouse Gas Protocol, emissions are categorised as scope 1, 2, and 3 emissions (Box&#x000a0;<xref rid="mja252621-fea-0001" ref-type="boxed-text">1</xref>).<xref rid="mja252621-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="mja252621-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><boxed-text position="float" content-type="Box" id="mja252621-fea-0001"><label>Box 1</label><caption><title>Definitions of greenhouse gas emissions by the Greenhouse Gas Protocol<xref rid="mja252621-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="mja252621-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-1"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Emissions scope</th><th align="left" valign="bottom" rowspan="1" colspan="1">Definition</th></tr></thead><tbody valign="top"><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Scope 1</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Direct emissions from sources owned or controlled by the company: for example, emissions from combustion in owned or controlled boilers, furnaces, and vehicles; chemical production in owned or controlled process equipment.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scope 2</td><td align="left" valign="top" rowspan="1" colspan="1">Indirect emissions from generation of purchased electricity consumed by the company.</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Scope 3</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Other indirect emissions related to activities of the company but from sources not owned or controlled by the company: for example, extraction and production of purchased goods; upstream/downstream transportation and distribution; processing and use of sold products.</td></tr></tbody></table></table-wrap>
</p></boxed-text><p>In Australia, the <italic toggle="yes">National Greenhouse and Energy Reporting Act 2007</italic> stipulates thresholds that determine which corporations are required to disclose emissions to the Clean Energy Regulator.<xref rid="mja252621-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> No Australian subsidiaries of pharmaceutical companies are registered under the Act.<xref rid="mja252621-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> On 27 March 2024, Treasury proposed an amendment to the <italic toggle="yes">Corporations Act 2001</italic> to make climate&#x02010;related corporate financial disclosure mandatory for large organisations, including pharmaceutical companies;<xref rid="mja252621-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> such an amendment would bring Australian requirements into line with those of the European Union, the United Kingdom, New Zealand, and Japan.<xref rid="mja252621-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="mja252621-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>The parent companies of multinational companies that operate in Australia are under increasing international pressure to reduce their environmental impact. The English National Health Service (NHS), for example, will stop purchasing from companies that &#x0201c;do not meet the NHS commitment to net zero by 2030&#x0201d;,<xref rid="mja252621-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> in accordance with the procurement policy of the United Kingdom government<xref rid="mja252621-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> and its commitment to net zero emissions throughout its supply chains by 2045.</p><p>An Oxford University team has recently provided the most robust assessment of the strategies of the twenty largest pharmaceutical companies for achieving net zero emissions.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The authors examined 2020&#x02013;21 data, and noted that nineteen companies had committed to reducing emissions, primarily by reducing scope 1 and 2 emissions, with less consistent aims for scope 3 emissions. The Oxford study was largely descriptive, and the authors recommended further comparative analyses and exploring differences by country and region.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>We therefore assessed the commitment of the largest pharmaceutical companies operating in Australia to achieving net zero emissions by evaluating their accountability metrics, ambition, and quantifiable actions taken. Our comparative analysis aims to inform decision making by Australian clinicians, health service leaders, and policy makers.</p><sec sec-type="methods" id="mja252621-sec-0011"><title>Methods</title><p>We undertook a cross&#x02010;sectional analysis of publicly available documents for the ten largest pharmaceutical companies operating in Australia during 12 December 2015 (date of the Paris Agreement) to 31 December 2023. We report our analysis according to the STROBE guidelines.<xref rid="mja252621-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>The ten largest companies were defined as those associated with the highest total pharmaceutical costs (ie, combined costs to patients and the PBS) for PBS&#x02010;subsidised pharmaceuticals, as reported in the PBS expenditure and prescriptions report for 1 July 2020 &#x02013; 30 June 2021,<xref rid="mja252621-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and updated using the 2022&#x02013;23 report.<xref rid="mja252621-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Merck Sharp &#x00026; Dohme (Australia) and Vertex Pharmaceuticals (Australia) were included in our analysis because they were ranked in the top ten in 2022&#x02013;23 (but not in 2020&#x02013;21). We also included Roche Products (eleventh largest in 2022&#x02013;23) instead of Sandoz (tenth largest in 2022&#x02013;23) because Sandoz had separated from Novartis Pharmaceuticals in a 100% spin&#x02010;off in October 2023,<xref rid="mja252621-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and the available data were consequently inadequate for analysis. We excluded Efficient Funding of Chemotherapy program items, including doctors&#x02019; bag and co&#x02010;payment prescriptions, as they are not included in annual PBS expenditure and prescriptions reports.<xref rid="mja252621-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><sec id="mja252621-sec-0012"><title>Information sources</title><p>We assessed data in publicly available company documents &#x02014; annual reports, environmental and social governance reports, supply chain communications, policy statements, investor updates, and annual financial reports &#x02014; supplemented by sustainability report data, press releases, interim sustainability updates, and sustainability strategies published on the Australian websites of each company. If information was not available on the Australian website, we searched for it on the parent company website to derive a best case scenario for inclusion in the analysis. The most recent CDP submission for each company was identified by searching the CDP website. Disclosed SBTi&#x02010;approved interim and net zero emission reduction targets were validated on the SBTi website and included in the analysis.</p><p>We included pharmaceutical company documents published in English during 12 December 2015 &#x02013; 31 December 2023 that included information about accountability, ambition, or action related to greenhouse gas emissions relevant to Australia for which the full text was available. We excluded superseded documents, documents primarily concerned with environmental topics other than greenhouse gas emissions, and documents otherwise deemed irrelevant to our study (eg, those discussing cultural environment). We sought data for the period 1 May 2022 &#x02013; 31 March 2024 to allow for lags in reporting.</p><p>We focused on greenhouse gas emission measurement and accountability metrics, climate change targets, and quantifiable actions to reduce emissions. We extracted basic company information, and information about climate change targets, greenhouse gas emissions, and reported initiatives or strategies for reducing emissions. To check our extraction method, we also searched for &#x0201c;environmental sustainability&#x0201d;, &#x0201c;greenhouse gas emissions&#x0201d;, &#x0201c;carbon footprint&#x0201d;, &#x0201c;carbon neutral&#x0201d;, &#x0201c;net zero&#x0201d;, &#x0201c;energy&#x0201d;, &#x0201c;scope 1&#x0201d;, &#x0201c;scope 2&#x0201d;, and &#x0201c;scope 3&#x0201d;. Scope 1, 2, and 3 greenhouse gas emission data were updated for the most recent annual data available.</p></sec><sec id="mja252621-sec-0013"><title>Content analysis</title><p>We used three international frameworks to map the extracted information. The first comprised our modification of criteria described in the PricewaterhouseCoopers <italic toggle="yes">Building blocks for net zero transformation framework</italic>,<xref rid="mja252621-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> which provides decarbonisation guidance for companies from various sectors, sizes, and locations; we selected this framework for its wide ranging and sector&#x02010;neutral approach. We modified the criteria by collapsing the nine building blocks to three domains: accountability, ambition, and action (Box&#x000a0;<xref rid="mja252621-fea-0002" ref-type="boxed-text">2</xref>). We then integrated the Carbon Disclosure Project (CDP) grading, a global disclosure and scoring system based on voluntary environmental impact report data published by businesses.<xref rid="mja252621-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Finally, we integrated the Science Based Targets initiative (SBTi) approval system, a global, non&#x02010;profit framework established to help companies meet industry&#x02010;specific emission reduction goals in line with the Paris Agreement.<xref rid="mja252621-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Framework adaptations were validated using face validity and compared using the methodology of the Oxford team.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><boxed-text position="float" content-type="Box" id="mja252621-fea-0002"><label>Box 2</label><caption><title>Comparative analysis of monitoring, commitment, and actions to net zero greenhouse gas emissions</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-2"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Domain/subdomain</th><th align="left" valign="bottom" rowspan="1" colspan="1">Criterion</th></tr></thead><tbody valign="top"><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">A. Accountability: monitoring and disclosure of emissions</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">A.1. Baseline disclosure</td><td align="left" valign="top" rowspan="1" colspan="1">Has the company conducted a baseline assessment of its scope 1 to 3 emissions?</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">A.2. Progress disclosure</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Does the company disclose its progress by performing annual scope 1 to 3 assessments?</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">A.3. Standardised disclosure</td><td align="left" valign="top" rowspan="1" colspan="1">Does the company use standard external frameworks when reporting emissions?</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">B. Ambition: making forward&#x02010;looking commitments to emission reductions</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">B.1. Science&#x02010;based target</td><td align="left" valign="top" rowspan="1" colspan="1">Does the company define a science&#x02010;based net zero emissions target with near (within ten years) and long term (beyond ten years) milestones?</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">B.2. Mitigation hierarchy</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Does the company prioritise emissions abatement over neutralisation and compensation measures?</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">B.3. Specific commitments</td><td align="left" valign="top" rowspan="1" colspan="1">Does the company outline areas of future business activity with specific timeframes to achieve its decarbonisation strategy?</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">C. Action: substantiating commitments with changes to business activity</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">C.1. Scope 1 and 2 action</td><td align="left" valign="top" rowspan="1" colspan="1">Has the company made changes to its operations or infrastructure to reduce scope 1 and 2 emissions?</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">C.2. Scope 3 action</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Has the company made changes to its operations or infrastructure to reduce scope 3 emissions?</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">C.3. Ancillary action</td><td align="left" valign="top" rowspan="1" colspan="1">Is the company fostering a corporate environment congruent with its decarbonisation strategy (governance, innovation, financing, public engagement)?</td></tr></tbody></table></table-wrap>
</p></boxed-text></sec><sec id="mja252621-sec-0015"><title>Statistical analysis</title><p>We focused on measurement, target setting, and achievement of emission reductions, and ranked the environmental sustainability of companies using a points and colour coding system (Box&#x000a0;<xref rid="mja252621-fea-0003" ref-type="boxed-text">3</xref>). Three authors independently scored each company; final score allocations were based on consensus, and in cases of variation we assigned the higher possible score to obtain a best case scenario. Inter&#x02010;rater reliability was assessed with Fleiss&#x02019; kappa.<xref rid="mja252621-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="mja252621-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><boxed-text position="float" content-type="Box" id="mja252621-fea-0003"><label>Box 3</label><caption><title>Scoring and colour coding system for comparative analysis of the commitment, monitoring, and actions of pharmaceutical companies operating in Australia for achieving net zero greenhouse gas emissions</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-3"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Scoring by domain/subdomain</th><th align="left" valign="bottom" rowspan="1" colspan="1">Colour coding system</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>A. Standardised accountability (9 points)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Red: 0&#x02013;3</p>
<p>Yellow: 4&#x02013;6</p>
<p>Green: 7&#x02013;9</p>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">A1. Baseline disclosure
<list list-type="bullet" id="mja252621-list-0001"><list-item id="mja252621-li-0001"><p>Baseline disclosures for scope 1, 2, 3 emissions: 1 point each</p></list-item></list>
</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A2. Progress disclosure
<list list-type="bullet" id="mja252621-list-0002"><list-item id="mja252621-li-0002"><p>Reductions in scope 1, 2, 3 emissions: 1 point each (increased or non&#x02010;disclosure of emissions: 0 points).</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">A3. Standardised disclosure
<list list-type="bullet" id="mja252621-list-0003"><list-item id="mja252621-li-0003"><p>CDP grade A: 3 points; CDP grade B or C: 2 points; CDP grade D or E: 1 point; CDP grade F or none disclosed: 0&#x000a0;points.</p></list-item></list>
</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>B. Validated ambition (11 points)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Red: 0&#x02013;3</p>
<p>Yellow: 4&#x02013;7</p>
<p>Green: 8&#x02013;11</p>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">B1. Science&#x02010;based targets
<list list-type="bullet" id="mja252621-list-0004"><list-item id="mja252621-li-0004"><p>SBTi&#x02010;validated net zero emissions target: 3 points; awaiting validation or committed to target:* 2 points; non&#x02010;SBTi target: 1 point; no net zero emissions target: 0 point.</p></list-item><list-item id="mja252621-li-0005"><p>SBTi&#x02010;validated interim target: 1 point.</p></list-item><list-item id="mja252621-li-0006"><p>Specific scope 1, 2, 3 targets: 1 point each.</p></list-item></list>
</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">B2. Mitigation hierarchy
<list list-type="bullet" id="mja252621-list-0005"><list-item id="mja252621-li-0007"><p>Evidence of specific or measurable abatement plans: 1 point; no evidence or non&#x02010;specific and non&#x02010;measurable abatement plans: 0 point.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">B3. Specific commitments
<list list-type="bullet" id="mja252621-list-0006"><list-item id="mja252621-li-0008"><p>Each commitment to decarbonise a specific area of future business activity including specific timelines: 1&#x000a0;point (maximum of 3 points).</p></list-item></list>
</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>C. Quantifiable actions (12 points)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Red: 0&#x02013;4</p>
<p>Yellow: 5&#x02013;8</p>
<p>Green: 9&#x02013;12</p>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">C1. Scope 1 and 2 action
<list list-type="bullet" id="mja252621-list-0007"><list-item id="mja252621-li-0009"><p>Changes to operations or infrastructure to reduce scope 1 and 2 emissions: 1 point each.</p></list-item></list>
</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C2. Scope 3 action
<list list-type="bullet" id="mja252621-list-0008"><list-item id="mja252621-li-0010"><p>Change to operations or infrastructure to reduce scope 3emissions: 1 point.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">C3. Ancillary action
<list list-type="bullet" id="mja252621-list-0009"><list-item id="mja252621-li-0011"><p>Ancillary action to reduce emissions (governance, engagement, finance, innovation, offsetting): 1 point each</p></list-item></list>
</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="mja252621-ntgp-0001"><fn id="mja252621-note-0001"><p>CDP&#x000a0;=&#x000a0;Carbon Disclosure Project grading. SBTi&#x000a0;=&#x000a0;Science Based Target Initiative.</p></fn><fn id="mja252621-note-0002"><p>* Have made a public commitment to setting SBTi targets within 24 months.</p></fn></table-wrap-foot></table-wrap>
</p></boxed-text></sec><sec id="mja252621-sec-0017"><title>Ethics approval</title><p>The Austin Health Discovery and Innovation Unit provided written exemption from formal ethics approval for this study.</p></sec></sec><sec sec-type="results" id="mja252621-sec-0018"><title>Results</title><p>During the 2022&#x02013;23 financial year, the ten pharmaceutical companies operating in Australia included in our analysis received $7.60 billion from the PBS, or 44.7% of total PBS expenditure on medications (Box&#x000a0;<xref rid="mja252621-fea-0004" ref-type="boxed-text">4</xref>). We assessed the full text of 221 of 992 records identified by our searches, and included 158 that met our inclusion criteria in our analysis (Box&#x000a0;<xref rid="mja252621-fea-0005" ref-type="boxed-text">5</xref>).</p><boxed-text position="float" content-type="Box" id="mja252621-fea-0004"><label>Box 4</label><caption><title>Ten largest pharmaceutical companies operating in Australia, as defined by total amount received for Pharmaceutical Benefits Scheme (PBS)&#x02010;subsidised medications*</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-4"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Amount received from PBS, 2022&#x02013;23</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Company</th><th align="left" valign="bottom" rowspan="1" colspan="1">Parent company (headquarters)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Trading status (stock exchange, symbol)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Absolute</th><th align="left" valign="bottom" rowspan="1" colspan="1">Proportion of PBS expenditure<sup>&#x02020;</sup>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Janssen&#x02010;Cilag</td><td align="left" valign="top" rowspan="1" colspan="1">Johnson &#x00026; Johnson Services (USA)</td><td align="left" valign="top" rowspan="1" colspan="1">Public (NYSE: JNJ)</td><td align="left" valign="top" rowspan="1" colspan="1">$1&#x02009;151&#x02009;263&#x02009;284</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6.77%</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Novartis Pharmaceuticals Australia</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Novartis (Switzerland)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Public (SIX: NOVN; NYSE: NVS)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">$1&#x02009;091&#x02009;720&#x02009;730</td><td align="char" char="." style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">6.42%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abbvie</td><td align="left" valign="top" rowspan="1" colspan="1">AbbVie (USA)</td><td align="left" valign="top" rowspan="1" colspan="1">Public (NYSE: ABBV)</td><td align="left" valign="top" rowspan="1" colspan="1">$782&#x02009;766&#x02009;506</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.60%</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Arrotex Pharmaceuticals</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Arrotex Holdings (Australia)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Private</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">$782&#x02009;437&#x02009;914</td><td align="char" char="." style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">4.60%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bayer Australia</td><td align="left" valign="top" rowspan="1" colspan="1">Bayer (Germany)</td><td align="left" valign="top" rowspan="1" colspan="1">Public (FRA: BAYN)</td><td align="left" valign="top" rowspan="1" colspan="1">$744&#x02009;590&#x02009;992</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.38%</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Merck Sharp &#x00026; Dohme (Australia)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Merck &#x00026; Co (USA)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Public (NYSE: MRK)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">$674&#x02009;891&#x02009;157</td><td align="char" char="." style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">3.97%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca</td><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca (UK)</td><td align="left" valign="top" rowspan="1" colspan="1">Public (LSE: AZN; NASDAQ: AZN)</td><td align="left" valign="top" rowspan="1" colspan="1">$670&#x02009;125&#x02009;411</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.94%</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Vertex Pharmaceuticals (Australia)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Vertex Pharmaceuticals (USA)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Public (NASDAQ: VRTX)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">$626&#x02009;491&#x02009;783</td><td align="char" char="." style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">3.69%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alphapharm</td><td align="left" valign="top" rowspan="1" colspan="1">Viatris (USA)</td><td align="left" valign="top" rowspan="1" colspan="1">Public (NASDAQ: VTRS)</td><td align="left" valign="top" rowspan="1" colspan="1">$587&#x02009;548&#x02009;945</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.46%</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Roche Products</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Roche Holding (Switzerland)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Public (SIX: ROG)</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">$486&#x02009;942&#x02009;238</td><td align="char" char="." style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">2.86%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Total for ten companies</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">$7&#x02009;598&#x02009;778&#x02009;960</italic>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<italic toggle="yes">44.7%</italic>
</td></tr></tbody></table><table-wrap-foot id="mja252621-ntgp-0002"><fn id="mja252621-note-0003"><p>FRA&#x000a0;=&#x000a0;Frankfurt Stock Exchange; LSE&#x000a0;=&#x000a0;London Stock Exchange; NASDAQ&#x000a0;=&#x000a0;National Association of Securities Dealers Automated Quotations; NYSE&#x000a0;=&#x000a0;New York Stock Exchange; SIX&#x000a0;=&#x000a0;Swiss Infrastructure Exchange; UK&#x000a0;=&#x000a0;United Kingdom; USA&#x000a0;=&#x000a0;United States of America.</p></fn><fn id="mja252621-note-0004"><p>* As reported in the PBS expenditure and prescriptions report for 1 July 2020 &#x02013; 30 June 2021,<xref rid="mja252621-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and updated using the 2022&#x02013;23 report.<xref rid="mja252621-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Sandoz removed from tenth position because of spin&#x02010;off from Novartis in October 2023; Roche was included in its place.</p></fn><fn id="mja252621-note-0005"><p>&#x02020; Total government expenses for the supply of medications, 2022&#x02013;23: $17&#x02009;billion.</p></fn></table-wrap-foot></table-wrap>
</p></boxed-text><boxed-text position="float" content-type="Box" id="mja252621-fea-0005"><label>Box 5</label><caption><title>Identification and assessment of pharmaceutical company documents published 12 December 2015 &#x02013; 31 December 2023 for inclusion in our assessment of commitment, monitoring, and actions for achieving net zero greenhouse gas emissions</title></caption><p>
<boxed-text position="anchor" content-type="graphic" id="mja252621-blkfxd-0002"><graphic xlink:href="MJA2-222-305-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p><p>CDP&#x000a0;=&#x000a0;Carbon Disclosure Project.</p><p>* Database search for period 12 December 2015 to 31 August 2022 only.</p></boxed-text><p>Five companies scored highly across all three domains (24 of 32 points or better). The highest overall score was for the seventh largest PBS beneficiary, AstraZeneca (30 of 32 points); that is, its performance with respect to decarbonisation targets, monitoring, and actions to reduce emissions was the best of the ten companies. Arrotex Pharmaceuticals scored 0 points because no publicly available data for the study period were identified (Box&#x000a0;<xref rid="mja252621-fea-0006" ref-type="boxed-text">6</xref>). Inter&#x02010;rater reliability for scoring was substantial (&#x003ba;&#x000a0;=&#x000a0;0.78; 95% confidence interval, 0.65&#x02013;0.90).</p><boxed-text position="float" content-type="Box" id="mja252621-fea-0006"><label>Box 6</label><caption><title>Assessment the ten largest pharmaceutical companies operating in Australia for commitment to, monitoring of, and actions for achieving net zero greenhouse gas emissions, 2015&#x02013;23*</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-5"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parent company</th><th align="left" valign="bottom" rowspan="1" colspan="1">Standardised accountability</th><th align="left" valign="bottom" rowspan="1" colspan="1">Validated ambition</th><th align="left" valign="bottom" rowspan="1" colspan="1">Quantifiable actions</th><th align="left" valign="bottom" rowspan="1" colspan="1">Total score</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Maximum score possible</italic>
</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">9</italic>
</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">11</italic>
</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">12</italic>
</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">32</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">8</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">11</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">11</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Novartis</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">8</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">10</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">10</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Johnson &#x00026; Johnson Services</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">8</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">9</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">11</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bayer</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">8</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">10</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">9</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Merck &#x00026; Co.</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">7</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">10</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">9</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AbbVie</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">7</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">6</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">9</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Roche Holding</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">4</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">9</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">7</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Viatris</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">7</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">4</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">8</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vertex Pharmaceuticals</td><td align="left" style="background-color:#EAF1DD" valign="top" rowspan="1" colspan="1">7</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">0</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">5</td><td align="left" style="background-color:#FFFFCC" valign="top" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Arrotex Pharmaceuticals</td><td align="left" style="background-color:#FFBDBF" valign="top" rowspan="1" colspan="1">0</td><td align="left" style="background-color:#FFBDBF" valign="top" rowspan="1" colspan="1">0</td><td align="left" style="background-color:#FFBDBF" valign="top" rowspan="1" colspan="1">0</td><td align="left" style="background-color:#FFBDBF" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot id="mja252621-ntgp-0003"><fn id="mja252621-note-0006"><p>* See Box&#x000a0;<xref rid="mja252621-fea-0003" ref-type="boxed-text">3</xref> for scoring criteria. Full ratings for each domain are included in the <xref rid="mja252621-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>, table&#x000a0;1.</p></fn></table-wrap-foot></table-wrap>
</p></boxed-text><p>Nine companies (exception: Arrotex Pharmaceuticals) conducted baseline measurements of scope 1 to 3 emissions during 2015&#x02013;21, and the same nine reported emissions reductions over time. Commitments to SBTi net zero emission targets for scope 1 to 3 emissions between 2040 and 2050 were approved for four companies, and eight companies had set interim targets, with differing levels and timeframes for change (<xref rid="mja252621-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>, tables&#x000a0;1 and 2). The leading companies achieved the largest scope 1 and 2 emissions reductions from baseline (AstraZeneca, 68% from 2015 to 2023; Novartis, 63% from 2016 to 2023; Johnson &#x00026; Johnson, 41% from 2016 to 2022). Six companies conducted and reported scope 3 baseline measurements; four reported that they were higher than at baseline or for earlier reporting periods (AstraZeneca, 18.6% from 2019 to 2023; Johnson &#x00026; Johnson, 11% from 2016 to 2022; Bayer, 12.5% from 2019 to 2021; Merck, 6% from 2019 to 2022).</p><p>Increasing renewable electricity use, improved governance structures, and engagement were the most frequently used quantifiable actions, digitisation and carbon offsetting the least used (Box&#x000a0;<xref rid="mja252621-fea-0007" ref-type="boxed-text">7</xref>).</p><boxed-text position="float" content-type="Box" id="mja252621-fea-0007"><label>Box 7</label><caption><title>Specific quantifiable actions reported in publicly available documents by ten largest pharmaceutical companies operating in Australia, 2015&#x02013;23: content analysis</title></caption><p>
<table-wrap position="anchor" id="jats-table-wrap-6"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Scope actions</th><th align="left" valign="bottom" rowspan="1" colspan="1">Companies</th><th align="left" valign="bottom" rowspan="1" colspan="1">Total score (out of 10)</th></tr></thead><tbody valign="top"><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Scope 1 and 2</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Renewable electricity</td><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co, AbbVie, Roche Holding, Viatris, Vertex Pharmaceuticals</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Manufacturing process improvements</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, AbbVie, Roche Holding, Viatris</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heating, ventilation, air conditioning improvements</td><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca, AbbVie, Roche Holding, Viatris, Vertex Pharmaceuticals., Merck &#x00026; Co.</td><td align="left" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Electrification of company fleet</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co, AbbVie</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scope 3</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Supply chain expectations</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co, AbbVie, Roche Holding, Viatris</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Business&#x02010;related travel reduction</td><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co, Viatris, Vertex Pharmaceuticals</td><td align="left" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Waste disposal improvements</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AstraZeneca, Johnson &#x00026; Johnson Services, Merck &#x00026; Co, AbbVie, Roche Holding, Viatris, Vertex Pharmaceuticals</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Digitisation</td><td align="left" valign="top" rowspan="1" colspan="1">Novartis</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Ancillary emission reduction actions</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Governance</td><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co., AbbVie., Roche Holding, Viatris., Vertex Pharmaceuticals</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Engagement</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co, AbbVie, Roche Holding, Viatris, Vertex Pharmaceuticals</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Financing</td><td align="left" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer, Merck &#x00026; Co, AbbVie</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Offsetting</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AstraZeneca, Novartis, Johnson &#x00026; Johnson Services, Bayer</td><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">4</td></tr></tbody></table></table-wrap>
</p></boxed-text></sec><sec sec-type="discussion" id="mja252621-sec-0023"><title>Discussion</title><p>We undertook a qualitative assessment of the commitments, accountability, and quantifiable actions for achieving net zero greenhouse gas emissions by the ten largest pharmaceutical companies operating in Australia. Based on our findings, three groups could be defined. The first &#x02014; companies leading emissions reduction efforts with SBTi&#x02010;approved near term targets, consistent emissions monitoring, well defined commitments, and quantified evidence of action &#x02014; includes AstraZeneca, Novartis, Johnson &#x00026; Johnson, Bayer, and Merck &#x00026; Co.; the second group &#x02014; companies that had made commitments to SBTi&#x02010;approved targets but their disclosure records are limited &#x02014; includes AbbVie and Roche; and the third group &#x02014; without public commitments to achieving net zero emissions, minimal or no SBTi&#x02010;approved targets, and minimal disclosure or monitoring of emissions &#x02014; includes Viatris, Vertex, and Arrotex.</p><p>Scope 1 and 2 emissions reductions were larger for companies in the first group than in their baseline reporting years (<xref rid="mja252621-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>, table&#x000a0;1). These reductions are similar to those reported by a recent study that examined the emissions targets of the twenty largest global pharmaceutical companies: six had reduced their scope 1 emissions by more than 20% from their respective baseline year of reporting, and eight companies had reduced scope 2 emissions by 30% or more.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> This indicates that reaching company targets (especially for scope 1 and 2 emissions) is possible, but achieving the published net zero emissions reduction targets across scopes 1 to 3 within the next two to eleven years, as planned, could require more rapid reductions.</p><p>AstraZeneca achieved the highest score in our assessment (30 of 32 points), meeting all criteria, including long term targets, SBTi approval for their 2045 net zero emissions goal, and defined baseline years for all three emission scopes. AstraZeneca has clear commitments with defined timeframes, including transitioning to 100% renewable electricity by 2025 and expecting 95% of suppliers to have science&#x02010;based targets according to Paris Agreement&#x02010;aligned pathways. They used multiple methods to reduce emissions, with progress toward renewable electricity for power and heating, electrification of fleet vehicles, changing manufacturing processes and waste disposal to replace natural gas, establishing supply chain expectations with its suppliers regarding greenhouse gas emission targets, less business&#x02010;related travel, heating and cooling efficiency measures, employee engagement programs, and governance structures that oversee progress toward emission reduction targets.</p><p>The two companies with the second highest scores, Novartis and Johnson &#x00026; Johnson, are each larger than AstraZeneca, respectively receiving 6.42% and 6.77% of total PBS expenditure for medications during 2022&#x02013;23 (AstraZeneca: 3.94%). Novartis, but not Johnson &#x00026; Johnson, has committed to an SBTi&#x02010;approved net zero emissions target, and has more recently reported an absolute reduction in scope 1 and 2 emissions from baseline.</p><p>As larger companies generally have larger emissions profiles, they need to achieve larger absolute reductions to achieve the same proportional emissions reduction targets over time. Smaller steps by larger companies toward net zero emissions may involve greater absolute reductions. Less ambitious commitments by other companies, particularly to science&#x02010;based net zero emissions targets, was associated with incomplete monitoring of emissions, less detail about decarbonisation strategies, less specific timeframes for ambitions, and unclear rationales for stated or intended actions.</p><p>Arrotex Pharmaceuticals, the only private company among the ten largest pharmaceutical companies, did not meet any of our criteria; no CDP grades were submitted, no net zero or emissions reduction targets, abatement plans, or decarbonisation strategies were available, and no action for any emission scope had been reported. Arrotex received a larger proportion of PBS medications expenditure than all but three of the companies in our analysis; it is the largest producer of generic medicines in Australia, supplying about one&#x02010;third of PBS&#x02010;subsidised prescription medications (about 70 million units) each year.<xref rid="mja252621-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> No data are publicly available, but Arrotex (an Australian company) could reduce scope 3 emissions by proposed moves to manufacturing medications in Australia.<xref rid="mja252621-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Given medication shortages in Australia and reliance on imported medications, local manufacturing should be supported, but it should be environmentally sustainable.</p><p>Private or unlisted companies are not subject to public shareholder scrutiny. Shareholders increasingly support reducing environmental impact as part of corporate social responsibility, including improved transparency and accountability.<xref rid="mja252621-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> For example, the 2021 AbbVie annual report noted shareholder concern about misalignment of its stated position on climate change and its donations to political parties.<xref rid="mja252621-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Standardised reporting measures, such as the CDP grading available to all companies, are important not just as impact measures but also for increasing disclosure transparency for shareholders and the public.<xref rid="mja252621-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Eight of the ten largest pharmaceutical companies operating in Australia (exceptions Roche, Arrotex) had reported data for assessment and scoring according to the CDP initiative.</p><p>Most actions undertaken by the ten companies aimed to reduce scope 1 and 2 emissions, most frequently improved manufacturing processes, heating and cooling efficiency, and electrification of the company fleet, as well as transitioning to electricity produced from renewable sources, which was reported by all nine public companies. However, scope 3 emissions across the entire value chain of a company, from upstream suppliers to end&#x02010;of&#x02010;life treatment of products, typically comprise the largest proportion of emissions.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Only six companies had conducted and reported scope 3 baseline measurements; similarly, in the recent Oxford team analysis, eleven of the top twenty global pharmaceutical companies were comprehensively reporting scope 3 emissions.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> In our study, four companies reported that scope 3 emissions were higher than at baseline or for earlier reporting periods. Explanations for the increases may include business growth<xref rid="mja252621-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and adjustments in the assessment methodology,<xref rid="mja252621-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> but the changes could also indicate that clear and universal standards for defining and measuring emissions across all industries are needed.</p><p>Difficulties for pharmaceutical companies in measuring and reducing scope 3 emissions have been acknowledged.<xref rid="mja252621-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Several international frameworks have included science&#x02010;aligned solutions to reduce them,<xref rid="mja252621-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> including engaging suppliers with smaller emissions profiles, adopting circular economy principles, embedding sustainability key performance indicators into procurement policies, and pricing carbon to provide a financial incentive for low carbon business models. Our study focused on quantitative analysis of actions being undertaken by pharmaceutical companies, and further work is required to qualitatively assess the extent to which the ten largest companies are applying environmental best practice. Reducing scope 3 emissions will ultimately require meaningful engagement with both suppliers and customers.</p><p>There is no regulatory framework for climate reporting by pharmaceutical companies in Australia, but we noted a change in emissions reporting practices during the period of our analysis, particularly during 2021&#x02013;2023. It probably reflects changes in external motivators, such as corporate branding and stronger international legislation regarding mandatory reporting, as well as internal motivators, such as recognition of cost savings, improved research and development processes, and leadership that promotes sustainability and strategic management.<xref rid="mja252621-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Mandatory disclosure of emissions has been introduced in Europe, requiring large public companies to report on their environmental sustainability.<xref rid="mja252621-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> At the industry level, several international pharmaceutical trade associations have co&#x02010;released a joint statement on developing more sustainable supply chains.<xref rid="mja252621-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> The proposed amendment to the Australian <italic toggle="yes">Corporations Act 2001</italic> would require corporations to publish climate disclosures from 2025,<xref rid="mja252621-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> including reporting on reductions of scope 1 to 3 emissions, governance, strategy, risk and transition planning, aligning Australian regulations with those of other countries, and increasing transparency for shareholders and the public, without limiting voluntary disclosure by corporations.</p><p>In England, the <italic toggle="yes">Delivering a &#x0201c;net zero&#x0201d; National Health Service</italic> report exemplifies how health sector&#x02010;wide leadership in decarbonisation has advanced corporate emissions reduction.<xref rid="mja252621-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The NHS plan has been referenced as justification for improved environmental metrics by AstraZeneca<xref rid="mja252621-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> and Johnson &#x00026; Johnson,<xref rid="mja252621-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> two companies that scored well in our analysis. Standardised reporting, sector leadership, and transparent disclosure requirements play influential roles in emissions reduction ambitions, and provide pathways for pharmaceutical companies operating in Australia to improve their net zero emissions plans.</p><p>To support such change, improved health sector leadership and an Australian regulatory framework are needed. The newly established National Health, Sustainability and Climate Unit and the National Health and Climate Strategy<xref rid="mja252621-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> are important for developing further mandatory, independent, objective metrics for decarbonisation. Such a unit and strategy could increase Australian pharmaceutical sector sustainability as companies use sustainability reporting to align their practices with regulatory requirements, while continuing to seek a competitive edge.</p><sec id="mja252621-sec-0024"><title>Limitations</title><p>Our analysis was limited by the availability of published data and voluntary disclosures. Additional actions for environmental sustainability may not have been publicly reported. Conversely, companies may report their environmental efforts in a more favourable light than justified by their performance (&#x0201c;greenwashing&#x0201d;),<xref rid="mja252621-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> a possibility supported by findings that managers adapt their disclosure strategies to different audiences.<xref rid="mja252621-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> For this reason, we used multiple reporting frameworks in our analysis to differentiate between aspiration and progress. We applied a multifaceted scoring system that directly compared targets and actions. We acknowledge that&#x000a0;our&#x000a0;scoring system might not fully capture the heterogeneity and complexity of the company actions disclosed, nor their efficacy in reducing emissions. One framework alone does not provide comprehensive coverage of commitment to achieving net zero emissions, but the companies that scored best in our analysis were also aligned with SBTi and CDP requirements.</p><p>Nevertheless, the industry&#x02010;non&#x02010;specific criteria of our comparative analysis could be useful for appraising other health&#x02010;related sectors, including hospitals and medical technology and device companies. This approach could be useful for policymakers and health professionals developing guidelines for and a culture of choosing low carbon options in clinical practice as part of broader strategies to reduce health care sector emissions, particularly as health systems, networks, and hospitals in Australia begin to publicise their commitments to net zero greenhouse gas emissions.<xref rid="mja252621-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</p></sec><sec sec-type="conclusions" id="mja252621-sec-0025"><title>Conclusion</title><p>We found that the ten largest pharmaceutical companies operating in Australia are moving towards net zero greenhouse gas emissions at different rates. We identified gaps in standardised reporting processes that should be closed to achieve both corporate accountability in achieving verifiable emissions reductions and bringing the Australian health system in line with those of other Western high income nations. Our findings indicate that more research and government support for standardised reporting frameworks for corporate decarbonisation strategies is required. Finally, our evaluation can assist clinicians make informed decisions about low carbon suppliers of medicines, and indicates the need for industry change in transitioning to a sustainable Australian health care sector.</p></sec></sec><sec sec-type="COI-statement" id="mja252621-sec-0026"><title>Competing interests</title><p>All authors are members of Doctors for the Environment Australia.</p></sec><sec id="mja252621-sec-0027"><title>Data sharing</title><p>We confirm that the data supporting the findings of this study were derived from public domain sources and are available in the article and its supplementary materials.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="mja252621-supitem-0001" position="float" content-type="local-data"><caption><p>
Supplementary results
</p></caption><media xlink:href="MJA2-222-305-s001.pdf"/></supplementary-material></sec></body><back><ack id="mja252621-sec-26"><title>Open access</title><p>Open access publishing facilitated by The University of Melbourne, as part of the Wiley &#x02013; the University of Melbourne agreement via the Council of Australian University Librarians.</p></ack><ref-list content-type="cited-references" id="mja252621-bibl-0001"><ref id="mja252621-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mja252621-cit-0001">
<string-name>
<surname>Malik</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lenzen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McAlister</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McGain</surname>
<given-names>F</given-names>
</string-name>. <article-title>The carbon footprint of Australian health care</article-title>. <source>Lancet Planet Health</source>
<year>2018</year>; <volume>2</volume>: <fpage>e27</fpage>&#x02010;<lpage>e35</lpage>.<pub-id pub-id-type="pmid">29615206</pub-id>
</mixed-citation></ref><ref id="mja252621-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0002">
<collab collab-type="authors">Australian Department of Health and Aged Care</collab>
. <article-title>PBS expenditure and prescriptions report 1 July 2022 to 30 June 2023. Updated 22 Dec 2023</article-title>. <ext-link xlink:href="https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions-report-1-july-2022-to-30-june-2023#:~:text=In-2022%2D23%2C-PBS-Government,which-amounted-to-%241.6-billion" ext-link-type="uri">https://www.pbs.gov.au/info/statistics/expenditure&#x02010;prescriptions/pbs&#x02010;expenditure&#x02010;and&#x02010;prescriptions&#x02010;report&#x02010;1&#x02010;july&#x02010;2022&#x02010;to&#x02010;30&#x02010;june&#x02010;2023#:~:text=In&#x02010;2022%2D23%2C&#x02010;PBS&#x02010;Government,which&#x02010;amounted&#x02010;to&#x02010;%241.6&#x02010;billion</ext-link>. (viewed Dec 2023).</mixed-citation></ref><ref id="mja252621-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0003">
<collab collab-type="authors">United Nations</collab>
. <article-title>The Paris Agreement</article-title>. Undated. <ext-link xlink:href="https://unfccc.int/process-and-meetings/the-paris-agreement/the-paris-agreement" ext-link-type="uri">https://unfccc.int/process&#x02010;and&#x02010;meetings/the&#x02010;paris&#x02010;agreement/the&#x02010;paris&#x02010;agreement</ext-link> (viewed Feb 2024).</mixed-citation></ref><ref id="mja252621-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0004">
<collab collab-type="authors">Science Based Targets Initiative</collab>
. <article-title>SBTi corporate net&#x02010;zero standard; version 1.2. Mar 2024</article-title>. <ext-link xlink:href="https://sciencebasedtargets.org/resources/files/Net-Zero-Standard.pdf" ext-link-type="uri">https://sciencebasedtargets.org/resources/files/Net&#x02010;Zero&#x02010;Standard.pdf</ext-link> (viewed July 2024).</mixed-citation></ref><ref id="mja252621-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0005">
<collab collab-type="authors">World Resources Institute; World Business Council for Sustainable Development</collab>
. <article-title>The greenhouse gas protocol: a corporate accounting and reporting standard. Revised edition. Mar 2004</article-title>. <ext-link xlink:href="https://ghgprotocol.org/sites/default/files/standards/ghg-protocol-revised.pdf" ext-link-type="uri">https://ghgprotocol.org/sites/default/files/standards/ghg&#x02010;protocol&#x02010;revised.pdf</ext-link> (viewed July 2022).</mixed-citation></ref><ref id="mja252621-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0006">
<collab collab-type="authors">Carbon Disclosure Project</collab>
. <article-title>Use CDP data</article-title>. Undated. <ext-link xlink:href="https://www.cdp.net/en/data" ext-link-type="uri">https://www.cdp.net/en/data</ext-link> (viewed Feb 2024).</mixed-citation></ref><ref id="mja252621-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mja252621-cit-0007">
<string-name>
<surname>Kumar</surname>
<given-names>K.</given-names>
</string-name>
<article-title>Emerging phenomenon of corporate sustainability reporting: evidence from top 100 NSE listed companies in India</article-title>. <source>J Public Aff</source>
<year>2022</year>; <volume>22</volume>: <elocation-id>e2368</elocation-id>.</mixed-citation></ref><ref id="mja252621-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0008">
<collab collab-type="authors">World Resources Institute; World Business Council for Sustainable Development</collab>
. <article-title>Greenhouse gas protocol. Corporate value chain (scope 3) accounting and reporting standard. Sept 2011</article-title>. <ext-link xlink:href="https://ghgprotocol.org/sites/default/files/standards/Corporate-Value-Chain-Accounting-Reporing-Standard_041613_2.pdf" ext-link-type="uri">https://ghgprotocol.org/sites/default/files/standards/Corporate&#x02010;Value&#x02010;Chain&#x02010;Accounting&#x02010;Reporing&#x02010;Standard_041613_2.pdf</ext-link> (viewed July 2022).</mixed-citation></ref><ref id="mja252621-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0009">
<collab collab-type="authors">Australian Government</collab>
. <article-title>National Greenhouse and Energy Reporting Act 2007 (no. 175; compilation no. 21). 9 Nov 2021</article-title>. <ext-link xlink:href="https://www.legislation.gov.au/Details/C2021C00509" ext-link-type="uri">https://www.legislation.gov.au/Details/C2021C00509</ext-link> (viewed Oct 2023).</mixed-citation></ref><ref id="mja252621-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0010">
<article-title>Clean Energy Regulator. National Greenhouse and Energy Register: controlling corporations registered under the NGER Act (including Reporting Transfer Certificate holders) for the 2020&#x02013;21 reporting year. 28 Feb 2022</article-title>. <ext-link xlink:href="https://cer.gov.au/document/national-greenhouse-and-energy-register-controlling-corporations-2020-21-0" ext-link-type="uri">https://cer.gov.au/document/national&#x02010;greenhouse&#x02010;and&#x02010;energy&#x02010;register&#x02010;controlling&#x02010;corporations&#x02010;2020&#x02010;21&#x02010;0</ext-link> (viewed Sept 2022).</mixed-citation></ref><ref id="mja252621-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0011">
<collab collab-type="authors">Australian Treasury</collab>
. <article-title>Mandatory climate&#x02010;related financial disclosures. Jan 2024</article-title>. <ext-link xlink:href="https://treasury.gov.au/sites/default/files/2024-01/c2024-466491-policy-state.pdf" ext-link-type="uri">https://treasury.gov.au/sites/default/files/2024&#x02010;01/c2024&#x02010;466491&#x02010;policy&#x02010;state.pdf</ext-link> (viewed Apr 2024).</mixed-citation></ref><ref id="mja252621-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0012">E<collab collab-type="authors">uropean Parliament; Council of the European Union</collab>
. <article-title>Directive (EU) 2022/2464 of the European Parliament and of the Council of 14 December 2022 amending Regulation (EU) No 537/2014, Directive 2004/109/EC, Directive 2006/43/EC and Directive 2013/34/EU, as regards corporate sustainability reporting</article-title>. 16 Dec 2022. <ext-link xlink:href="https://eur-lex.europa.eu/eli/dir/2022/2464/oj/eng" ext-link-type="uri">https://eur&#x02010;lex.europa.eu/eli/dir/2022/2464/oj/eng</ext-link> (viewed Apr 2024).</mixed-citation></ref><ref id="mja252621-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0013">
<collab collab-type="authors">National Health Service England</collab>
. <article-title>Carbon reduction plan and net zero commitment requirements for the procurement of NHS goods, services and works, version 2</article-title>. 31 Oct 2023. <ext-link xlink:href="https://www.england.nhs.uk/long-read/carbon-reduction-plan-requirements-for-the-procurement-of-nhs-goods-services-and-works" ext-link-type="uri">https://www.england.nhs.uk/long&#x02010;read/carbon&#x02010;reduction&#x02010;plan&#x02010;requirements&#x02010;for&#x02010;the&#x02010;procurement&#x02010;of&#x02010;nhs&#x02010;goods&#x02010;services&#x02010;and&#x02010;works</ext-link> (viewed Oct 2023).</mixed-citation></ref><ref id="mja252621-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0014">
<collab collab-type="authors">Cabinet Office of the United Kingdom Government</collab>
. <article-title>Taking account of carbon reduction plans in the procurement of major government contracts (PPN 06/21)</article-title>. 5 June 2021. <ext-link xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054374/PPN-0621-Taking-account-of-Carbon-Reduction-Plans-Jan22__1_.pdf" ext-link-type="uri">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054374/PPN&#x02010;0621&#x02010;Taking&#x02010;account&#x02010;of&#x02010;Carbon&#x02010;Reduction&#x02010;Plans&#x02010;Jan22__1_.pdf</ext-link> (viewed June 2022).</mixed-citation></ref><ref id="mja252621-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mja252621-cit-0015">
<string-name>
<surname>Booth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jager</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Faulkner</surname>
<given-names>SD</given-names>
</string-name> et&#x000a0;al. <article-title>Pharmaceutical company targets and strategies to address climate change: content analysis of public reports from 20 pharmaceutical companies</article-title>. <source>Int J Environ Res Public Health</source>
<year>2023</year>; <volume>20</volume>: <fpage>3206</fpage>.<pub-id pub-id-type="pmid">36833902</pub-id>
</mixed-citation></ref><ref id="mja252621-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mja252621-cit-0016">
<string-name>
<surname>Von Elm</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Egger</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al; <article-title>STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>Lancet</source>
<year>2007</year>; <volume>370</volume>: <fpage>1453</fpage>&#x02010;<lpage>1457</lpage>.<pub-id pub-id-type="pmid">18064739</pub-id>
</mixed-citation></ref><ref id="mja252621-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0017">
<collab collab-type="authors">Australian Department of Health</collab>
. <article-title>PBS expenditure and prescriptions report 1 July 2020 to 30 June 2021</article-title>. <ext-link xlink:href="https://www.pbs.gov.au/statistics/expenditure-prescriptions/2020-2021/PBS_Expenditure_and_Prescriptions_Report_1-July-2020_to_30-June-2021.pdf" ext-link-type="uri">https://www.pbs.gov.au/statistics/expenditure&#x02010;prescriptions/2020&#x02010;2021/PBS_Expenditure_and_Prescriptions_Report_1&#x02010;July&#x02010;2020_to_30&#x02010;June&#x02010;2021.pdf</ext-link> (viewed May 2022).</mixed-citation></ref><ref id="mja252621-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0018">
<collab collab-type="authors">Novartis</collab>
. <article-title>Novartis executes Sandoz spin&#x02010;off, completing strategic transformation into a leading, focused innovative medicines company&#x000a0;[media release]</article-title>. 4 Oct 2023. <ext-link xlink:href="https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company" ext-link-type="uri">https://www.novartis.com/news/media&#x02010;releases/novartis&#x02010;executes&#x02010;sandoz&#x02010;spin&#x02010;completing&#x02010;strategic&#x02010;transformation&#x02010;leading&#x02010;focused&#x02010;innovative&#x02010;medicines&#x02010;company</ext-link> (viewed Feb&#x000a0;2024).</mixed-citation></ref><ref id="mja252621-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0019">
<collab collab-type="authors">PricewaterhouseCoopers</collab>
. <article-title>The building blocks for net zero transformation. Sept 2020</article-title>. <ext-link xlink:href="https://www.pwc.co.uk/sustainability-climate-change/assets/pdf/building-blocks-net-zero-companies-transformation.pdf" ext-link-type="uri">https://www.pwc.co.uk/sustainability&#x02010;climate&#x02010;change/assets/pdf/building&#x02010;blocks&#x02010;net&#x02010;zero&#x02010;companies&#x02010;transformation.pdf</ext-link> (viewed July 2022).</mixed-citation></ref><ref id="mja252621-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mja252621-cit-0020">
<string-name>
<surname>Fleiss</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Measuring nominal scale agreement among many raters</article-title>. <source>Psychol Bull</source>
<year>1971</year>; <volume>76</volume>: <fpage>378</fpage>&#x02010;<lpage>382</lpage>.</mixed-citation></ref><ref id="mja252621-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mja252621-cit-0021">
<string-name>
<surname>Landis</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>GG</given-names>
</string-name>. <article-title>The measurement of observer agreement for categorical data</article-title>. <source>Biometrics.</source>
<year>1977</year>; <volume>33</volume>: <fpage>159</fpage>&#x02010;<lpage>174</lpage>.<pub-id pub-id-type="pmid">843571</pub-id>
</mixed-citation></ref><ref id="mja252621-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mja252621-cit-0022">
<string-name>
<surname>Riordan</surname>
<given-names>P.</given-names>
</string-name>
<article-title>Billionaire Bastas&#x02019; Arrotex posts near 50 per cent rise in profit</article-title>. <source>Financial Review</source> (Australia), 28 July <year>2023</year>. <ext-link xlink:href="https://www.afr.com/companies/healthcare-and-fitness/billionaire-bastas-arrotex-posts-near-50-per-cent-rise-in-profit-20230728-p5ds1k" ext-link-type="uri">https://www.afr.com/companies/healthcare&#x02010;and&#x02010;fitness/billionaire&#x02010;bastas&#x02010;arrotex&#x02010;posts&#x02010;near&#x02010;50&#x02010;per&#x02010;cent&#x02010;rise&#x02010;in&#x02010;profit&#x02010;20230728&#x02010;p5ds1k</ext-link> (viewed Apr 2024).</mixed-citation></ref><ref id="mja252621-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0023">
<collab collab-type="authors">Arrotex Pharmaceuticals</collab>
. <article-title>The Australian medicines &#x00026; vaccines manufacturing and development initiative [submission to Treasury]</article-title>. Aug 2020. <ext-link xlink:href="https://treasury.gov.au/sites/default/files/2020-09/115786_ARROTEX_PHARMACEUTICALS.pdf" ext-link-type="uri">https://treasury.gov.au/sites/default/files/2020&#x02010;09/115786_ARROTEX_PHARMACEUTICALS.pdf</ext-link> (viewed Feb 2025).]</mixed-citation></ref><ref id="mja252621-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="mja252621-cit-0024">
<string-name>
<surname>Freeburn</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ramsay</surname>
<given-names>I</given-names>
</string-name>. <article-title>An analysis of ESG shareholder resolutions in Australia</article-title>. <source>UNSW Law Journal</source>
<year>2021</year>; <volume>44</volume>: <fpage>1142</fpage>&#x02010;<lpage>1179</lpage>.</mixed-citation></ref><ref id="mja252621-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0025">
<collab collab-type="authors">AbbVie</collab>
. <article-title>Celebrating our employees: 2021 annual report on form 10&#x02010;K. 2022</article-title>. <ext-link xlink:href="https://investors.abbvie.com/static-files/91cf9d6a-8e6f-4059-9575-eda83b7e4623" ext-link-type="uri">https://investors.abbvie.com/static&#x02010;files/91cf9d6a&#x02010;8e6f&#x02010;4059&#x02010;9575&#x02010;eda83b7e4623</ext-link> (viewed Aug 2022).</mixed-citation></ref><ref id="mja252621-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="mja252621-cit-0026">
<string-name>
<surname>Depoers</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Jeanjean</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>J&#x000e9;r&#x000f4;me</surname>
<given-names>T</given-names>
</string-name>. <article-title>Voluntary disclosure of greenhouse gas emissions: contrasting the Carbon Disclosure Project and corporate reports</article-title>. <source>J Bus Ethics</source>
<year>2016</year>; <volume>134</volume>: <fpage>445</fpage>&#x02010;<lpage>461</lpage>.</mixed-citation></ref><ref id="mja252621-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0027">
<collab collab-type="authors">AstraZeneca</collab>
. <article-title>Sustainability report data summary 2021</article-title>. <ext-link xlink:href="https://www.astrazeneca.com/content/dam/az/Sustainability/2022/pdf/Sustainability_Data_Summary_2021.pdf" ext-link-type="uri">https://www.astrazeneca.com/content/dam/az/Sustainability/2022/pdf/Sustainability_Data_Summary_2021.pdf</ext-link> (viewed Aug&#x000a0;2022).</mixed-citation></ref><ref id="mja252621-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0028">
<collab collab-type="authors">Novartis</collab>
. <article-title>Novartis in society integrated report 2021. 2022</article-title>. <ext-link xlink:href="https://www.novartis.com/sites/novartis_com/files/novartis-integrated-report-2021.pdf" ext-link-type="uri">https://www.novartis.com/sites/novartis_com/files/novartis&#x02010;integrated&#x02010;report&#x02010;2021.pdf</ext-link> (viewed June 2022).</mixed-citation></ref><ref id="mja252621-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0029">
<collab collab-type="authors">Novartis</collab>
. <article-title>Environmental social governance investor event: September 30, 2021</article-title>. <ext-link xlink:href="https://www.novartis.com/sites/novartis_com/files/2024-12-novartis-impact-sustainability.pdf" ext-link-type="uri">https://www.novartis.com/sites/novartis_com/files/2024&#x02010;12&#x02010;novartis&#x02010;impact&#x02010;sustainability.pdf</ext-link> (viewed Aug 2022).</mixed-citation></ref><ref id="mja252621-bib-0030"><label>30</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0030">
<string-name>
<surname>Farsan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kerkhof</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Value change in the value chain: best practices in scope 3 greenhouse gas management; version 3. Science Based Targets</article-title>, Nov <year>2018</year>. <ext-link xlink:href="https://sciencebasedtargets.org/resources/files/SBT_Value_Chain_Report-1.pdf" ext-link-type="uri">https://sciencebasedtargets.org/resources/files/SBT_Value_Chain_Report&#x02010;1.pdf</ext-link> (viewed May 2024).</mixed-citation></ref><ref id="mja252621-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0031">
<collab collab-type="authors">International Federation of Pharmaceutical Manufacturers and Associations</collab>
. <article-title>Innovative pharmaceutical industry statement on COP28 declaration on climate and health. 3 Dec 2023</article-title>. <ext-link xlink:href="https://www.ifpma.org/news/innovative-pharmaceutical-industry-statement-on-cop28-declaration-on-climate-and-health" ext-link-type="uri">https://www.ifpma.org/news/innovative&#x02010;pharmaceutical&#x02010;industry&#x02010;statement&#x02010;on&#x02010;cop28&#x02010;declaration&#x02010;on&#x02010;climate&#x02010;and&#x02010;health</ext-link> (viewed Sept 2024).</mixed-citation></ref><ref id="mja252621-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0032">
<collab collab-type="authors">National Health Service England</collab>
. <article-title>Delivering a &#x0201c;net zero&#x0201d; National Health Service (PAR133). 2022</article-title>. <ext-link xlink:href="https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf" ext-link-type="uri">https://www.england.nhs.uk/greenernhs/wp&#x02010;content/uploads/sites/51/2022/07/B1728&#x02010;delivering&#x02010;a&#x02010;net&#x02010;zero&#x02010;nhs&#x02010;july&#x02010;2022.pdf</ext-link> (viewed Oct 2023).</mixed-citation></ref><ref id="mja252621-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0033">
<collab collab-type="authors">AstraZeneca</collab>
. <article-title>What science can do: AstraZeneca annual report and form 20&#x02010;F information 2021</article-title>. 2022. <ext-link xlink:href="https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2021/pdf/AstraZeneca_AR_2021.pdf" ext-link-type="uri">https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual&#x02010;report&#x02010;2021/pdf/AstraZeneca_AR_2021.pdf</ext-link> (viewed Aug&#x000a0;2022).</mixed-citation></ref><ref id="mja252621-bib-0034"><label>34</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0034">
<article-title>Johnson &#x00026; Johnson. Health for humanity report. 2022</article-title>. <ext-link xlink:href="https://healthforhumanityreport.jnj.com/2023/_assets/downloads/johnson-johnson-2023-health-for-humanity-report.pdf?h=Ka9OvM1t" ext-link-type="uri">https://healthforhumanityreport.jnj.com/2023/_assets/downloads/johnson&#x02010;johnson&#x02010;2023&#x02010;health&#x02010;for&#x02010;humanity&#x02010;report.pdf?h=Ka9OvM1t</ext-link> (viewed Aug 2022).</mixed-citation></ref><ref id="mja252621-bib-0035"><label>35</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0035">
<collab collab-type="authors">Australian Department of Health and Aged Care</collab>
. <article-title>National health and climate strategy. Updated 3 Dec 2023</article-title>. <ext-link xlink:href="https://www.health.gov.au/our-work/national-health-and-climate-strategy" ext-link-type="uri">https://www.health.gov.au/our&#x02010;work/national&#x02010;health&#x02010;and&#x02010;climate&#x02010;strategy</ext-link> (viewed May 2024).</mixed-citation></ref><ref id="mja252621-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mja252621-cit-0036">
<string-name>
<surname>de Freitas Netto</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Sobral</surname>
<given-names>MFF</given-names>
</string-name>, <string-name>
<surname>Ribeiro</surname>
<given-names>ARB</given-names>
</string-name>, <string-name>
<surname>Soares</surname>
<given-names>GRL</given-names>
</string-name>. <article-title>Concepts and forms of greenwashing: a systematic review</article-title>. <source>Environ Sci Eur</source>
<year>2020</year>; <volume>32</volume>: <fpage>19</fpage>.</mixed-citation></ref><ref id="mja252621-bib-0037"><label>37</label><mixed-citation publication-type="miscellaneous" id="mja252621-cit-0037">
<collab collab-type="authors">Royal Women's Hospital</collab>
. <article-title>The Women's announces bold new sustainability target [media release]. 29 Sept 2022</article-title>. <ext-link xlink:href="https://www.thewomens.org.au/news/the-womens-announces-bold-new-sustainability-target" ext-link-type="uri">https://www.thewomens.org.au/news/the&#x02010;womens&#x02010;announces&#x02010;bold&#x02010;new&#x02010;sustainability&#x02010;target</ext-link> (viewed Oct&#x000a0;2022).</mixed-citation></ref></ref-list></back></article>